## Data Sharing Statement

| Item | Question | Authors’ Response (place “-” if not applicable) |
|------|----------|-------------------------------------------------|
| 1    | Would you like to share data collected for your study to others? | Yes |
| 2    | If not, would you like to share the reason for your decision? | - |
| 3    | What data in particular will be shared? | The efficacy and safety information of enrolled patients. |
| 4    | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | - |
| 5    | When will data availability begin? | From the publication date. |
| 6    | When will data availability end? | No limit. |
| 7    | To whom will you share the data? | Medical oncologists and lung surgeons who are interested in this study. |
| 8    | For what type of analysis or purpose? | For analysis to evaluate the efficacy and safety of neoadjuvant therapy with the PD-1 inhibitor camrelizumab, nab-paclitaxel, and carboplatin for patients with stage IB-IIIA NSCLC and to establish a multi-omics artificial intelligence system for neoadjuvant therapy based on radiomics, metabolism, and genetic and clinic-pathological characteristics. |
| 9    | How or where can the data/documents be obtained? | Emails could be sent to the address below to obtain the shared data: yaoherui@mail.sysu.edu.cn |
| 10   | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |